Cryoport, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cryoport, Inc. on March 29, 2012. The report primarily addresses corporate governance changes and the disclosure of a business update conference call.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the compensation for the newly elected director: a quarterly cash board fee of $15,000.
Material Changes
- Board Composition: Stephen E. Wasserman was elected to the Board of Directors on March 29, 2012, filling the vacancy created by the resignation of Carlton M. Johnson, Jr. on March 1, 2012.
- Committee Assignments: Mr. Wasserman was appointed Chairman of the Compensation Committee and named a member of both the Audit Committee and the Governance and Nominating Committee.
- Executive Background: Mr. Wasserman brings approximately 20 years of experience in global in vitro diagnostic and medical device companies, including prior roles as CFO of Datascope Corporation and Group Vice President at Olympus America, Inc.
Guidance, Outlook, and Risks
On March 28, 2012, the Company conducted a webcast conference call to provide a business update. The script for this call, furnished as Exhibit 99.2, contains forward-looking statements regarding future events. Management highlighted risks and uncertainties including:
- Changing economic conditions.
- Trends in product markets.
- Variations in the Company's cash flow.
- Market acceptance and technical development risks.
The Company disclaims any obligation to update these forward-looking statements. No related party transactions or special compensatory arrangements were identified in connection with Mr. Wasserman's election.
Investor Verification Checklist
- Verify the full text of the business update conference call script (Exhibit 99.2) for specific operational details not included in this summary.
- Review the Company's most recent Form 10-K (filed June 27, 2011) for detailed financial statements and comprehensive risk factors.
- Confirm the absence of any undisclosed agreements or understandings regarding Mr. Wasserman's selection as a director.